SCHEMBL211306

SCHEMBL211306

C[C]1N=c2ccccc2=N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
ACHE P22303 2/20 0.39
LMNA P02545 1/20 0.37
ALOX12 P18054 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
CHEK1 O14757 3/20 0.34
ABL1 P00519 1/20 0.34
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT1 P17948 1/20 0.34
GRK5 P34947 1/20 0.34
KDR P35968 1/20 0.34
MAP2K2 P36507 1/20 0.34
CDK8 P49336 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
PRKX P51817 1/20 0.34
NEK2 P51955 1/20 0.34
LIMK1 P53667 1/20 0.34
MAP2K1 Q02750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21316061 0.72 MAPT (0.41) TSHRALOX12ALDH1A1NQO2NPC1
SCHEMBL9658951 0.69 ALDH1A1 (0.44) LMNAL3MBTL1ALDH1A1CYP1A2NPC1
SCHEMBL2445152 0.67 TP53 (0.39) L3MBTL1ALDH1A1CYP1A2
SCHEMBL6094001 0.67 MAPT (0.30)
SCHEMBL1696827 0.67 ALDH1A1 (0.30) ALDH1A1HPGD
SCHEMBL7398024 0.67 MAPT (0.39) TSHRLMNAL3MBTL1FLT1KDR
SCHEMBL858858 0.67 MAPT (0.34) L3MBTL1ALDH1A1NPC1TDP1KMT2A
SCHEMBL37950 0.67 MEN1 (0.35) LMNAL3MBTL1GSK3BMAP2K1CYP1A2
SCHEMBL3499657 0.67 CASP1 (0.39) TSHRACHEL3MBTL1ALDH1A1CYP1A2
SCHEMBL317892 0.67 MAPT (0.40) LMNAMAP2K1ALDH1A1CYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111434658-A Organic electroluminescent materials and devices 机光科技股份有限公司 2020-07-21 CN claimed
EP-3256462-A1 SUBSTITUTED 2-THIOIMIDAZOLYL-CARBOXAMIDES AS PEST CONTROL AGENTS Bayer CropScience Aktiengesellschaft (DE) 2017-12-20 EP claimed
WO-2016128298-A1 SUBSTITUTED 2-THIOIMIDAZOLYL-CARBOXAMIDES AS PEST CONTROL AGENTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-08-18 WO claimed
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents SERINA THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2024-03-12 US disclosed
WO-2023178017-A1 DEACYLATION OF CARBOHYDRATE COMPOUNDS ELYSIUM HEALTH INC. (US) 2023-09-21 WO disclosed
CN-111743901-B Spray-dried formulations 普尔莫凯恩股份有限公司 2023-09-12 CN disclosed
EP-3054937-B1 SPRAY DRY FORMULATIONS PULMOKINE INC (US) 2023-07-26 EP disclosed
US-11692090-B2 Dielectric cross-linked fluoropolymer DAIKIN AMERICA, INC. (US) 2023-07-04 US disclosed
CN-110072844-B Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni 英特维特国际股份有限公司 2023-06-02 CN disclosed
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE INTERVET INC. (US) 2023-01-05 US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 WO disclosed
WO-2002018383-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2002-03-07 WO disclosed
US-6124323-A ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS WARNER-LAMBERT COMPANY (US) 2000-09-26 US disclosed
EP-0869792-A4 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 1999-09-22 EP disclosed
EP-0869792-A2 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-10-14 EP disclosed
WO-1997023216-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed
EP-0120589-B1 IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP disclosed
US-4621084-A CARDIOTONIC, ANTIULCER FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-11-04 US disclosed
EP-0120589-A1 Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents CD44, CD47, LNPEP TSHR 1915/4885ACHE 4460/4885LMNA 3015/4885
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same ERBB3, ERBB2, PANK2 TSHR 3404/4885ACHE 2492/4885LMNA 4630/4885
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE PIGS, BTD, BRD1 TSHR 1591/4885ACHE 2779/4885LMNA 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.